Company Overview
| Stock Name | Zyloxtb |
|---|---|
| Stock Code | 02190 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是中國神經和外周血管介入醫療器械市場的領導者,為中國及海外的醫生和患者提供治療及應對神經和外周血管疾病的醫療器械,涵蓋急性缺血性腦卒中、顱內動脈瘤、頸動脈狹窄、外周動脈和靜脈疾病及透析相關疾病。 |
| Listing Date | 2021-07-05 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國浙江省杭州市余杭區科技大道18號1幢1、2層 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東248號大新金融中心40層 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | zyloxtb.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 42.70 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 21,350 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2021-06-22 to 2021-06-25 |
| Global Offering Shares | 60,000,000 shares |
| HK Public Offer Shares (Initial) | 6,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | 12,000lots (Pool A6,000lots,Pool B6,000lots) |
| International Placing Shares (Initial) | 54,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 323,401,001 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 43.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 2,562,000,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 21,350 |
| 2 lots | 1,000 | HK$ 42,700 |
| 3 lots | 1,500 | HK$ 64,050 |
| 4 lots | 2,000 | HK$ 85,400 |
| 5 lots | 2,500 | HK$ 106,750 |
| 6 lots | 3,000 | HK$ 128,100 |
| 7 lots | 3,500 | HK$ 149,450 |
| 8 lots | 4,000 | HK$ 170,800 |
| 9 lots | 4,500 | HK$ 192,150 |
| 10 lots | 5,000 | HK$ 213,500 |
| 12 lots | 6,000 | HK$ 256,200 |
| 14 lots | 7,000 | HK$ 298,900 |
| 16 lots | 8,000 | HK$ 341,600 |
| 18 lots | 9,000 | HK$ 384,300 |
| 20 lots | 10,000 | HK$ 427,000 |
| 30 lots | 15,000 | HK$ 640,500 |
| 40 lots | 20,000 | HK$ 854,000 |
| 50 lots | 25,000 | HK$ 1,067,500 |
| 60 lots | 30,000 | HK$ 1,281,000 |
| 70 lots | 35,000 | HK$ 1,494,500 |
| 80 lots | 40,000 | HK$ 1,708,000 |
| 90 lots | 45,000 | HK$ 1,921,500 |
| 100 lots | 50,000 | HK$ 2,135,000 |
| 120 lots | 60,000 | HK$ 2,562,000 |
| 140 lots | 70,000 | HK$ 2,989,000 |
| 160 lots | 80,000 | HK$ 3,416,000 |
| 180 lots | 90,000 | HK$ 3,843,000 |
| 200 lots | 100,000 | HK$ 4,270,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 400 lots | 200,000 | HK$ 8,540,000 |
| 600 lots | 300,000 | HK$ 12,810,000 |
| 800 lots | 400,000 | HK$ 17,080,000 |
| 1,000 lots | 500,000 | HK$ 21,350,000 |
| 1,200 lots | 600,000 | HK$ 25,620,000 |
| 1,400 lots | 700,000 | HK$ 29,890,000 |
| 1,600 lots | 800,000 | HK$ 34,160,000 |
| 1,800 lots | 900,000 | HK$ 38,430,000 |
| 2,000 lots | 1,000,000 | HK$ 42,700,000 |
| 4,000 lots | 2,000,000 | HK$ 85,400,000 |
| 6,000 lots | 3,000,000 | HK$ 128,100,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 6.74B |
| Est. Threshold | HK$ 9.44B |
| Analysis Result | HK market cap below threshold, need +40% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 13,809,222,742 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 5,188,903,914 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣100.5百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 161,000,000 |
| Listing Expenses / Funds Raised | ~6.28% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 | 2020 |
|---|---|---|
| Revenue | 4,917 | 27,631 |
| Cost of sales | -3,725 | -11,344 |
| Gross profit | 1,192 | 16,287 |
| Other income and gains, net | 7,656 | 9,997 |
| Selling and distribution expenses | -6,759 | -20,453 |
| Administrative expenses | -16,962 | -30,992 |
| Operating profit | -65,701 | -100,162 |
| Net finance costs | -946 | -306 |
| Profit before tax | -66,647 | -100,468 |
| Income tax expense | 0 | 0 |
| Profit for the year | -66,647 | -100,468 |
| Profit attributable to owners | -66,647 | -100,468 |
Balance Sheet
| Item | 2019 | 2020 |
|---|---|---|
| Cash and cash equivalents | 46,130 | 59,556 |
| Trade and bills receivables | 1,013 | 129 |
| Inventories | 9,955 | 28,993 |
| Total current assets | 125,284 | 370,142 |
| Total assets | 207,060 | 503,971 |
| Total current liabilities | 33,387 | 51,631 |
| Total liabilities | 41,385 | 79,277 |
| Total equity | 165,675 | 424,694 |
| Equity attributable to owners | 165,675 | 424,694 |
| Interest-bearing borrowings | 17,500 | 30,000 |
Cash Flow Statement
| Item | 2019 | 2020 |
|---|---|---|
| Net cash from operating activities | -53,092 | -82,334 |
| Net cash from investing activities | -90,593 | -249,176 |
| Net cash from financing activities | 179,444 | 345,537 |
| Net increase in cash | 35,759 | 14,027 |
| Purchase of PP&E | -41,582 | -45,140 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 60.0 |
|---|---|
| First Day Open | HK$ 55.0 |
| First Day Change | 40.52% |
| First Day Volume | 58971000.0 |
| First Day Turnover | 3342110000.0 |
| Use of Proceeds | 1、約37.0%,或888.1百萬港元,將被分配予我們的核心產品;
2、約11.0%,或262.2百萬港元,將被分配予我們其他5款主要產品的持續研發、生產及商業化;
3、約40.0%,或959.5百萬港元,將被分配予我們其他38款產品及在研管線,以開發我們的產品組合,進而提供全線解決方案;
4、約3.0%,或71.9百萬港元,將分配予進一步升級研發設施,包括位于杭州及珠海的軟件及硬件基礎設施,以及在珠海計劃進行的辦公室擴建與升級;
5、約4.0%,或95.9百萬港元,將分配予潛在戰略收購、投資、授權引進或合作;
6、約5.0%,或119.9百萬港元,將用于我們的營運資金及一般公司用途。 |
Underwriting Syndicate
Overall Coordinators (6)
Joint Bookrunners (6)
Joint Lead Managers (6)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | AIHC Master Fund | 124,192,950 HKD | — | 4.85% | — | 6 months | 2022-01-05 |
| 2 | Athos Asia Event Driven Master Fund | 31,042,900 HKD | — | 1.21% | — | 6 months | 2022-01-05 |
| 3 | Boyu Capital Opportunities Master Fund | 124,192,950 HKD | — | 4.85% | — | 6 months | 2022-01-05 |
| 4 | Cormorant Asset Management, LP | 62,085,800 HKD | — | 2.42% | — | 6 months | 2022-01-05 |
| 5 | Fidelity International | 155,235,850 HKD | — | 6.06% | — | 6 months | 2022-01-05 |
| 6 | Hillhouse Funds | 232,843,100 HKD | — | 9.09% | — | 6 months | 2022-01-05 |
| 7 | Hudson Bay Master Fund LTD | 77,607,250 HKD | — | 3.03% | — | 6 months | 2022-01-05 |
| 8 | Lake Bleu Prime Healthcare Master Fund Limited | 155,235,850 HKD | — | 6.06% | — | 6 months | 2022-01-05 |
| 9 | Octagon Investments Master Fund LP | 54,314,400 HKD | — | 2.12% | — | 6 months | 2022-01-05 |
| 10 | Sage Partners Master Fund | 15,521,450 HKD | — | 0.61% | — | 6 months | 2022-01-05 |
| 11 | Snow Lake China Master Fund, Ltd. | 77,607,250 HKD | — | 3.03% | — | 6 months | 2022-01-05 |
| 12 | 常春藤资产管理(香港)有限公司 | 15,521,450 HKD | — | 0.61% | — | 6 months | 2022-01-05 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | Jonathon Zhong Zhao | — |
| Company Secretary | 袁泉衛、張啟昌 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 趙博士及其一致行動人士(包括鐘博士、李博士、衛女士、珠海通橋投資、杭州涪江、珠海歸創、湖州歸橋、WEA及南京語意慧)緊接全球發售前合共持有約36.55%權益;王暉先生及其弘暉股東合共持有約11.11%權益;OAP IV (HK) Limited持有約7.83%、先進製造產業投資基金持有約6.33%、清池資本持有約4.67%、AIHC Master Fund持有約3.86%。 |
|---|




